Drugs / BI 1356225
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06628622 | Jan 2025 → Feb 2027 | opiate dependence | Boehringer Ingelheim | Suspended | No outcome recorded Stop: Business |
| Phase 1 | NCT04447261 | Jun 2020 → Apr 2021 | obesity disorder | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT04065295 | Sep → Dec 2019 | — | Boehringer Ingelheim | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BI 1356225 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04447261 ↗ |
| Route | Oral | “Oral Dose” NCT04065295 ↗ |